In this issue:
- Lung cancer risk in interstitial lung disease
- Outcomes in non-Indigenous Australians
- Impact of surgical resection delay
- H1 antihistamines: a protective effect?
- Blood markers for risk recurrence
- Zongertinib in HER2-mutant advanced NSCLC
- OptiTROP-Lung05 trial: interim analysis
- TRUST-I trial: longer-term analysis
- IFCT-1701 “DICIPLE” trial
- Unresectable stage III EGFR-mutated NSCLC
Please login below to download this issue (PDF)